華仁藥業(300110.SZ):華仁世紀集團擬減持不超6%的股份
格隆匯7月19日丨華仁藥業(300110.SZ)公佈,華仁世紀集團有限公司(“華仁世紀集團”)於2020年12月24日發布了《關於持股5%以上股東減持計劃期限屆滿及後續減持計劃預披露公吿》,計劃自公吿之日起15個交易日後的6個月內,通過證券交易所集中競價交易減持股數不超過公司總股本的2%,即不超過2364.42萬股。截至2021年7月17日,華仁世紀集團前次減持計劃已實施完畢,減持計劃期限內減持數量為0股。
近日,公司收到華仁世紀集團《關於減持股份計劃的吿知函》,華仁世紀集團計劃自減持計劃公吿之日起十五個交易日後的六個月內通過集中競價交易、大宗交易方式減持不超過華仁藥業總股本6%的股份,擬減持數量將不超過7093.26萬股,其中:通過集中競價交易方式減持的,自減持計劃公吿之日起15個交易日後的6個月內,減持股數不超過公司總股份的2%;通過大宗交易方式減持的,自減持計劃公吿之日起3個交易日之後的6個月內,減持股數不超過公司總股份的4%。
若此期間公司有送股、資本公積金轉增股本等股份變動事項,則對該減持數量進行相應調整,減持價格視市場情況確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.